Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.Booster dose
- Recommended between 6 and 12 months after the primary dose†2
- Where this is not possible, booster can be delayed up to 3 years2 [LOCs to update the booster delay timeline as per local SmPC]
- Given as a single dose, intramuscularly2
Havrix Junior helps provide rapid and long-term protection from hepatitis A1–3
Up to 50 years’ predicted long-term protection when administered in paediatric populations*3
100% seroconversion within 14 days of vaccination**1 (acute hepatitis A incubation period usually 15–50 days)4
[LOCs to update number of days in seroconversion claim when appropriate, to align with local SmPC]
[LOCs to check coadministration options against their local PI]
Havrix Junior for children and adolescents aged ≤15 years can be co-administered with a wide range of other vaccines:2,5
- Typhoid
- Yellow fever
- Cholera (injectable)
- Tetanus
- Measles, mumps and rubella
- Varicella
Havrix Junior has a two-dose regimen2
For children/adolescents aged 1–15 years2
[LOCs to update as per the therapeutic indication of Havrix Junior in the local SmPC]
Primary immunisation schedule
Given as a single dose, intramuscularly2
Havrix (Adult and Junior) has extensive clinical and real-world experience6,7
- The world’s first licensed vaccine against hepatitis A6
- 30 years of real-world experience6
- Registered in >85 countries7
- ~400 million doses†† distributed worldwide since its launch in 19927
- The world’s most widely studied hepatitis A vaccine6
- 150 clinical trials involving >30,000 subjects6
CI, confidence interval; UV, universal vaccination; mIU/mL, milli-international units per millilitre
*A descriptive analysis was used to predict long-term seropositivity results for children based on studies of vaccines containing inactivated hepatitis A antigen either as standalone hepatitis A vaccine or combination hepatitis A and B vaccine. In order to extrapolate outcomes in children using data in adults, studies with data on adult vaccine doses of hepatitis A and B vaccine 720 EU or hepatitis A vaccine 1,440 EU were selected3
**138 mIU/mL (95% CI: 120–159). In a comparative trial in which 332 seronegative children from 1–15 years of age were randomised to receive two doses of hepatitis A vaccine 6 months apart1
†Havrix Junior can be administered to children and adolescents aged 1–15 years.2 Havrix Junior is administered in a primary dose with a booster dose recommended 6 to 12 months after primary immunisation. Havrix Junior provides active immunisation against infections caused by hepatitis A in both age groups2
††In both paediatric and adult populations7
References
- Abarca K et al. Int J Infect Dis 2008; 12:270–277.
- Havrix Junior SmPC, January 2022.
- Agrawal A et al. Infect Dis Ther 2020; 9:785–796.
- Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases (The Pink Book). 14th Edition. 2021. Public Health Foundation, Washington, D.C.; p.125–142.
- Havrix Global Data Sheet, December 2019.
- André F et al. Expert Rev Vaccines 2002; 1:9–23.
- GSK data on file; 2023N531266_00.
For more information, please refer to the prescribing information or contact GlaxoSmithKline
via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
GlaxoSmithKline Biologicals SA. Rixensart, Belgium
© 2023 GSK group of companies or its licensor
Trademark is owned by or licensed to the GSK group of companies
PM-RCH-HAV-WCNT-230002 | Date of preparation: November 2023
